Yuhan Corporation

Na Ry Ha

Hyun Ho Choi

Tae Dong Han

Sol Park

Eun Kyung Kim

Hee Jae Tak

Dong Hoon Kim

Su Bin Choi

Mi Kyeong Ju

Tae Wang Kim

So Young Kim

Eun Hye Jung

Eui Chul Lee

Cheol Hee Lim

Hyok Jun Cho

Na Yeon Yang

Da Na Jeong

Do Hoon Kim

Tae Kyun Kim

Ji Yeong Gal

Jae Won Jeong

Hyun Seung Lee

Jun Chul Park

Sang Myoun Lim

Eui Chui Lee

Da In Chung

Ji Eun Yang

Jun Chui Park

Tae Han Dong

Yoo Hoi Park

Jae Eun Joo

The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same

The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g. for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same

The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same

The present technology provides pyrrolidine and piperidine compounds or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. In particular, said compounds may be usefully applied in the treatment and prevention of FAP-mediated diseases.

Pyrrolidine and piperidine compounds

The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same

The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Growing community of inventors

Seoul, South Korea

Na Ry Ha